INDV · NASDAQ · STOCK
Indivior Pharmaceuticals Inc
$38.42
52W $22.22 – $42.81
58/100
$4.79B
13.5
1.03
Is INDV Bullish or Bearish?
Mixed.
Innellis AI committee rates Indivior Pharmaceuticals Inc (INDV) Watch with a composite score of 58/100
, based on 6 analysts with 50% agreement.
Last updated August 11, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +2.00 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -18.00 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — high leverage (debt-to-equity 5.43) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- P/E of 12.8 is inexpensive for the broad market — Value
- ROE of 159.1% shows genuine earnings power backing the valuation — Value
- EPS growing 237.5% YoY — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price-to-book of 49.6x prices in significant intangible value — Value
- Debt-to-equity of 5.43 adds balance-sheet risk to the value case — Value
- MACD histogram negative -- bearish momentum — Technical
- High leverage (debt-to-equity 5.43) amplifies downside in a stress scenario — Risk
- Current ratio of 0.71 is tight -- limited short-term liquidity cushion — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
58/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 61%
of 192 Healthcare peers
Value Analyst
neutral
55
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ P/E of 12.8 is inexpensive for the broad market
− Price-to-book of 49.6x prices in significant intangible value
Growth Analyst
bullish
75
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ EPS growing 237.5% YoY
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst
bearish
32
/ 100 · Moderate confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 5.43) amplifies downside in a stress scenario
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
neutral
60
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
42.6
Neutral
MACD Histogram
-0.205
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Mixed
Support
$32.42
Resistance
$40.86
Bollinger %B
0.27
Inside Bands
Price vs Moving Averages
EMA 9
$38.75
Below
EMA 21
$39.24
Below
EMA 50
$38.90
Below
EMA 200
$33.79
Above
Fundamental Analysis
Valuation
100
Profitability
75
Financial Health
51
Cash Flow
15
Valuation
P/E Ratio
13.5×
P/B Ratio
-23.16×
PEG Ratio
0.07
Dividend Yield
0.00%
52W High
$42.81
52W Low
$22.22
Quality & Growth
ROE
-21428.6%
ROA
1744.2%
Gross Margin
8385.9%
Operating Margin
3888.9%
Revenue Growth YoY
—
Debt / Equity
-2.45
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of 13.5 (inexpensive relative to a 15-40x range); Price-to-book of -23.2x; PEG ratio of 0.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -214.3%; Return on assets of 17.4%; Net margin of 26.7%; Gross margin of 83.9%; Current ratio of 0.84 (tight short-term liquidity); Debt-to-equity of -2.45; Free cash flow per share is negative (-0.89); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full INDV Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →